PenderFund Capital Management’s Maravai LifeSciences MRVI Stock Holding History

PenderFund Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.28M	Hold	205,000	–	–	0.16%	54
2026 Q1	$580K	Sell	205,000 -15,500	-7%	-$52.5K	0.09%	70
2025 Q4	$717K	Sell	220,500 -199,357	-47%	-$671K	0.11%	55
2025 Q3	$1.2M	Sell	419,857 -450,343	-52%	-$1.15M	0.2%	46
2025 Q2	$2.1M	Buy	870,200 +43,900	+5%	+$92.3K	0.5%	37
2025 Q1	$1.49M	Buy	826,300 +246,000	+42%	+$972K	0.41%	39
2024 Q4	$4.55M	Buy	+580,300	New	+$3.73M	0.98%	20
2022 Q4	–	Sell	-1,200	Closed	-$42K	–	142
2022 Q3	$42K	Hold	1,200	–	–	0.01%	162
2022 Q2	$44K	Buy	+1,200	New	+$38K	0.01%	152

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

PenderFund Capital Management's MRVI Position: Q2 2026 in Review

PenderFund Capital Management held its Maravai LifeSciences (MRVI) position steady in Q2 2026 at 205,000 shares worth $1.28M. The position accounts for 0.16% of the portfolio, ranked #54.

PenderFund Capital Management first reported a position in MRVI in Q2 2022 and has held it in 9 quarters since. The position peaked at $4.55M in Q4 2024. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

PenderFund Capital Management held 205,000 shares of Maravai LifeSciences worth $1.28M as of Q2 2026.
PenderFund Capital Management left its Maravai LifeSciences share count unchanged in Q2 2026.
Maravai LifeSciences made up 0.16% of PenderFund Capital Management's portfolio in Q2 2026, its #54 holding.
PenderFund Capital Management first reported a position in Maravai LifeSciences in Q2 2022 and has held it in 9 quarters since.
PenderFund Capital Management's Maravai LifeSciences position peaked at $4.55M in Q4 2024.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on PenderFund Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.